


AMENDMENTS TO THE CLAIMS

1. (previously presented) A compound of formula (I)




or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, wherein:

R¹ and R² are each independently hydrogen or methoxy, provided R¹ and R² are not both hydrogen or both methoxy;

n is 1, 2, 3, or 4;

X is a bond, O, S, C=O, -N(R)-, wherein R is hydrogen or -(C₁-C₃)alkyl, -C(OH)- or -SO₂; and

Y is benzoxazolyl, benzothiazolyl, benzofurazanyl, benzofuranyl, benzothiadiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, pyridyl, isatiny, oxindolyl, indazolyl, indolyl, phenyl, thienyl or furanyl; wherein Y is optionally substituted independently with from one to three halogen, trifluoromethyl, methoxy, -C(=O)CH₃, cyano, -C(CH₃)₂OH, -CH(CH₃)OH, -CH(CF₃)OH, -C(C=O)CF₃, -SO₂NH₂, -C(=O)OCH₃, -CH₂COOH, , thiazolyl or oxadiazolyl.

2. (previously presented) The compound of claim 1, wherein X is a bond; and Y is benzofurazanyl, thienyl, pyridyl, or phenyl, wherein said phenyl is optionally substituted independently with one or two halogen, trifluoromethyl, methoxy, -C(=O)CH₃, cyano, -C(CH₃)₂OH, -CH(CH₃)OH, -CH(CF₃)OH, -C(C=O)CF₃, -SO₂NH₂, -C(=O)OCH₃, -CH₂COOH, thiazolyl or oxadiazolyl; or a pharmaceutically acceptable salt thereof.

3. (previously presented) The compound of claim 1, wherein X is a bond; n is 2 or 3; and Y is thienyl, pyridyl or phenyl, wherein said phenyl is optionally substituted independently with

one or two methoxy, halogen, $-\text{C}(\text{CH}_3)_2\text{OH}$, $\text{CH}(\text{CF}_3)\text{OH}$ or $-\text{C}(\text{C}=\text{O})\text{CF}_3$; or a pharmaceutically acceptable salt thereof.

4. (original) N^2, N^4 -bis-(3,5-Dimethoxy-benzyl)-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,5-dimethoxy-benzyl)- N^2 -(2-pyridin-4-yl-ethyl)-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,5-dimethoxy-benzyl)- N^2 -(2-thiophen-2-yl-ethyl)-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,5-dimethoxy-benzyl)- N^2 -2-phenethyl-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,5-dimethoxy-benzyl)- N^2 -[2-(3,5-dimethoxy-phenyl)-ethyl]-pyrido[2,3-d]pyrimidine-2,4-diamine;
2-(3-{3-[4-(3,4-dimethoxy-benzylamino)-pyrido[2,3-d]pyrimidin-2-ylamino]-propyl}-phenyl)-propan-2-ol;
 N^4 -(3,4-dimethoxy-benzyl)- N^2 -[2-(4-fluoro-phenyl)-ethyl]-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,4-dimethoxy-benzyl)- N^2 -phenethyl-pyrido[2,3-d]pyrimidine-2,4-diamine; or
 N^4 -(3,4-dimethoxy-benzyl)- N^2 -(3-phenyl-propyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.

5. (previously presented) A pharmaceutical composition comprising a compound of formula (I) of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

6. (currently amended) A method of treating bone fracture or ~~bone defect, occurring individually or together, or~~ of promoting bone in-growth in a mammal in need of such treatment which method comprises administering to said mammal a therapeutically effective amount of a compound of formula (I) of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug; or a pharmaceutical composition comprising said compound of formula (I), said prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

7. (previously presented) The method of claim 6, wherein bone fracture is treated.

8. (previously presented) The method of claim 7, wherein said bone fracture is delayed or non-union bone fracture.

9.-12. (canceled)

13. (currently amended) The method of claim ~~42~~ 6, wherein the compound of formula (I) is N^4 -(3,5-dimethoxy-benzyl)- N^2 -(2-pyridin-4-yl-ethyl)-pyrido[2,3-d]pyrimidin-2,4-diamine; 2-(3-{3-[4-(3,4-dimethoxy-benzylamino)-pyrido[2,3-d]pyrimidin-2-ylamino]-propyl}-phenyl)-propan-2-ol; N^4 -(3,4-dimethoxy-benzyl)- N^2 -(3-phenyl-propyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.

14.-15. (canceled)

16. (previously presented) The compound of claim 2, wherein n is 2 or 3; and Y is thienyl, pyridyl or phenyl, wherein said phenyl is optionally substituted independently with one or two methoxy, halogen, $-C(CH_3)_2OH$, $CH(CF_3)OH$ or $-C(C=O)CF_3$; or a pharmaceutically acceptable salt thereof.

17. (previously presented) A pharmaceutical composition comprising a compound of claim 4, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

18. (currently amended) A method of treating bone fracture ~~or bone defect, occurring individually or together,~~ or of promoting bone in-growth in a mammal in need of such treatment which method comprises administering to said mammal a therapeutically effective amount of a compound claim 4, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug; or a pharmaceutical composition comprising said compound claim 4, said prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

19.-20. (canceled)

21. (previously presented) N^4 -(3,4-dimethoxy-benzyl)- N^2 -(3-phenyl-propyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; or a pharmaceutically acceptable salt thereof.